Site-specific pegylation of G-CSF by reversible denaturation.
about
A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycolPEGylation of Truncated Streptokinase Leads to Formulation of a Useful Drug with Ameliorated AttributesConformational and aggregation properties of a PEGylated alanine-rich polypeptideAcceleration of diabetic-wound healing with PEGylated rhaFGF in healing-impaired streptozocin diabetic rats.Non-native aggregation of recombinant human granulocyte-colony stimulating factor under simulated process stress conditions.Biophysical characterization of Met-G-CSF: effects of different site-specific mono-pegylations on protein stability and aggregation.Delivery of therapeutic proteins.Product development issues for PEGylated proteins.Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study.Granulocyte colony-stimulating factor (GCSF) fused with Fc Domain produced from E. coli is less effective than Polyethylene Glycol-conjugated GCSF.Towards the next generation of biomedicines by site-selective conjugation.G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responsesSemisynthetic prion protein (PrP) variants carrying glycan mimics at position 181 and 197 do not form fibrils.PEGylation-aided refolding of globular adiponectin.Characterization of disulfide linkages in recombinant human granulocyte-colony stimulating factor.EGFR Targeting and Shielding of pDNA Lipopolyplexes via Bivalent Attachment of a Sequence-Defined PEG Agent.Disulfide-bridging PEGylation during refolding for the more efficient production of modified proteins.
P2860
Q28478454-653EDE80-665C-4A54-835E-BCF03D0730C3Q28552198-808D1AB0-4DDF-4DAA-A8F4-AB1CCD3A053EQ33893033-A0AD55B5-7D8F-40E4-A37E-FFCD16062963Q34076711-AFAA1A01-A0FE-47A0-ACD2-E3875F5A7120Q34197661-C38677EC-92AF-4074-B041-AFAFC2630CDAQ34384451-70A68A09-7F21-4ABE-B5BC-19A19BB92EE2Q37668486-D3D4BBC5-88BB-4B7A-88FE-8834A5C329B4Q37790702-05B95B79-2D31-4525-9DDE-F998A9CED801Q38393615-334226A8-57BD-44BD-9732-6A77FA34DA2DQ38696361-D9851823-08FB-4111-9DA6-300FEF02C027Q38706553-A1E65922-625B-42B2-A153-285F363A1220Q41956513-92D7E208-8413-4B19-AD2C-7B9024839F9EQ42285440-670C167D-32B6-476A-9EFF-76A4D3FD4006Q46271521-0B39BAC0-29DB-46C0-995E-B9BF119BD015Q46954734-B209B5E6-3486-4D64-BF97-72B33B064408Q48119581-DC623FE3-52E7-4B54-8FE0-3F568A9ADDF2Q50850473-460474EF-963C-4AC9-9879-22E05EB64682
P2860
Site-specific pegylation of G-CSF by reversible denaturation.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Site-specific pegylation of G-CSF by reversible denaturation.
@ast
Site-specific pegylation of G-CSF by reversible denaturation.
@en
Site-specific pegylation of G-CSF by reversible denaturation.
@nl
type
label
Site-specific pegylation of G-CSF by reversible denaturation.
@ast
Site-specific pegylation of G-CSF by reversible denaturation.
@en
Site-specific pegylation of G-CSF by reversible denaturation.
@nl
prefLabel
Site-specific pegylation of G-CSF by reversible denaturation.
@ast
Site-specific pegylation of G-CSF by reversible denaturation.
@en
Site-specific pegylation of G-CSF by reversible denaturation.
@nl
P2093
P356
P1476
Site-specific pegylation of G-CSF by reversible denaturation.
@en
P2093
Christian Marongiu
Francesca Caboi
Francesco M Veronese
Mauro Sergi
P304
P356
10.1021/BC070123+
P577
2007-10-18T00:00:00Z